AIP
AKBA icon

Ameritas Investment Partners’s Akebia Therapeutics AKBA Stock Holding History

Ameritas Investment Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29K Hold
20,887
– – ﹤0.01% 2415
2025
Q4 		$33.6K Hold
20,887
– – ﹤0.01% 2376
2025
Q3 		$57K Sell
20,887
-4,638
-18% -$15.4K ﹤0.01% 2039
2025
Q2 		$92.9K Buy
25,525
+5,145
+25% +$14.1K ﹤0.01% 1808
2025
Q1 		$39.1K Hold
20,380
– – ﹤0.01% 2247
2024
Q4 		$38.7K Hold
20,380
– – ﹤0.01% 2338
2024
Q3 		$26.9K Hold
20,380
– – ﹤0.01% 2506
2024
Q2 		$20.8K Buy
+20,380
New +$25.2K ﹤0.01% 2590
2022
Q2 		– Sell
-11,500
Closed -$8K – 3059
2022
Q1 		$8K Hold
11,500
– – ﹤0.01% 2849
2021
Q4 		$26K Hold
11,500
– – ﹤0.01% 2515
2021
Q3 		$33K Hold
11,500
– – ﹤0.01% 2405
2021
Q2 		$44K Hold
11,500
– – ﹤0.01% 2263
2021
Q1 		$39K Hold
11,500
– – ﹤0.01% 2221
2020
Q4 		$32K Hold
11,500
– – ﹤0.01% 2230
2020
Q3 		$29K Hold
11,500
– – ﹤0.01% 2176
2020
Q2 		$156K Buy
11,500
+1,352
+13% +$14K 0.01% 1131
2020
Q1 		$77K Hold
10,148
– – ﹤0.01% 1414
2019
Q4 		$64K Hold
10,148
– – ﹤0.01% 1764
2019
Q3 		$40K Hold
10,148
– – ﹤0.01% 2007
2019
Q2 		$49K Buy
10,148
+3,480
+52% +$19.8K ﹤0.01% 1918
2019
Q1 		$55K Hold
6,668
– – ﹤0.01% 1838
2018
Q4 		$37K Buy
6,668
+2,855
+75% +$22.3K ﹤0.01% 1976
2018
Q3 		$34K Hold
3,813
– – ﹤0.01% 2197
2018
Q2 		$38K Hold
3,813
– – ﹤0.01% 2157
2018
Q1 		$36K Hold
3,813
– – ﹤0.01% 2091
2017
Q4 		$57K Buy
3,813
+1,013
+36% +$16.8K ﹤0.01% 1851
2017
Q3 		$46K Hold
2,800
– – ﹤0.01% 1945
2017
Q2 		$40K Hold
2,800
– – ﹤0.01% 2047
2017
Q1 		$26K Buy
+2,800
New +$27.3K ﹤0.01% 2249

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ameritas Investment Partners's AKBA Position: Q1 2026 in Review

Ameritas Investment Partners held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 20,887 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

Ameritas Investment Partners first reported a position in AKBA in Q1 2017 and has held it in 29 quarters since. The position peaked at $156K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Ameritas Investment Partners held 20,887 shares of Akebia Therapeutics worth $29K as of Q1 2026.
  • Ameritas Investment Partners left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2415 holding.
  • Ameritas Investment Partners first reported a position in Akebia Therapeutics in Q1 2017 and has held it in 29 quarters since.
  • Ameritas Investment Partners's Akebia Therapeutics position peaked at $156K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.